231 results about "Cystine+Cysteine" patented technology

A method of administering parenterally, particularly intramuscularly, glutamine and cystine and glycine plus selenium; or lactalbumin plus selenium; or lactalbumin and glutamine and cystine and glycine plus selenium, through a long-acting pharmaceutically acceptable carrier to a patient. The method comprises injecting a mixture of glutamine, cystine, glycine, lactalbumin and selenium in order to maintain the mixture systemically or locally for a sufficient time period so as to maintain blood levels of glutathione within an improved therapeutic range.

The present invention provides cystine derivatives, which may be in a free form, a salt form, a solvate form. The cystine derivatives of the present invention may be used to suppress activation of inflammatory factors. Accordingly, the present invention provides: compositions containing the cystine derivatives; a method for suppressing the activation of inflammatory factors by administering the composition; a method for preventing, ameliorating and / or therapeutically treating diseases, skin injuries or disorders involved in the activation of inflammatory factors by administering the composition; a method for preventing, delaying, ameliorating and / or therapeutically treating skin change via aging or aesthetically unfavorable skin change as induced or promoted by inflammatory factors by administering the composition; and pharmaceutical agents containing the cystine derivatives.

Compositions for generating a cooked flavor in a foodstuff, comprising specified flavor precursors that react on heating to generate the flavor and maintain a reactive association after inclusion in the foodstuff. The compositions may include combination of a sulphur source, e.g. hydrogen sulphide, methane thiol, a sulfur-containing amino acid, thiamine, cystine, sodium sulphide, ammonium sulphide, ammonium polysulphide, onions, garlic, shallots, eggs, methionine, and mixtures thereof, and at least one reductone, e.g. a furanone, a ketone, a pyrone, an aldehyde, a carbonyl compound, isomaltol, maltol, pyruvaldehyde, hydroxyacetone, 3-deoxyglucosone, 5-hydroxy-5,6-dihydromaltol, 2,3-butanedione, 3-hydroxy-2-butanone, a process flavor, cooked vegetable concentrates, soy sauce, and mixtures thereof.

Methods and preparations for treating disorders of the eye and / or causing posterior vitreous disconnection or disinsertion. Preparations containing a) urea, b) urea derivatives (e.g., hydroxyurea, thiourea), c) a non-steroidal anti-inflamatory agents, d) antmetabolites, e) urea, urea derivatives, non-enzymatic proteins, nucleosides, nucleotides and their derivatives (e.g., adenine, adenosine, cytosine, cytadine, guanine, guanitadine, guanidinium, thymidine, thimitadine, uradine, uracil, cystine), uric acid, calcium acetal salicylate, ammonium sulfate or other compound capable of causing non-enzymatic dissolution of the hyaloid membrane or e) any of the possible combinations thereof, are administered to the eye in therapeutically effective amounts.

The invention provides a feed additive for improving the quality of the fur of a furry animal. The additive is obtained by mixing a semi-finished vitamin product, a semi-finished trace element product, dihydropyridine, methionine, cystine and corn gluten meal according to a weight ratio of 1:1:0.3-1:0.2-0.9:0.1-0.6:2, wherein the semi-finished vitamin product is prepared by uniformly mixing the following components: 5-22 parts of vitamin A, 3-8 parts of vitamin D, 10-25 parts of vitamin E, 3-8 parts of vitamin B1, 8-15 parts of biotin, 1-3 parts of vitamin B6, and 120-160 parts of the corn gluten meal, and the semi-finished trace element product is prepared by uniformly mixing the following components: 10-20 parts of methionine chelated zinc, 2-5 parts of methionine chelated copper, and 70-90 parts of zeolite powder. The additive of the invention allows the quality of the fur of the furry animals (martens, foxes and raccoon dogs) to be substantially improved, the hair density to be increased, the hair length to be improved, the hide toughness to be increased and the culture benefit to be improved.

A composition includes a plurality of amino acids. The plurality of amino acids includes at least one essential amino acid and at least one non-essential amino acid. The plurality of amino acids also includes at least one branch-chain amino acid. The composition also includes a source of carbohydrates. The compositions also includes purified water. The plurality of amino acids comprises about 1 wt % of the composition. A composition includes a plurality of amino acids, sodium citrate, sodium chloride, potassium phosphate, flavoring, a source of carbohydrates, and purified water. In some embodiments of the composition, the plurality of amino acids includes alanine, arginine, aspartate, cystine, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonin, tryptophan, tyrosine, and valine.

The invention provides a Chinese herbal medicine compound amino acid feed additive and a preparation method thereof. The Chinese herbal medicine compound amino acid feed additive is mainly prepared from the following raw materials in parts by weight: 20 to 35 parts of water soluble vitamin, 20 parts of compound amino acid, and 40 to 45 parts of traditional Chinese medicine powder, wherein the traditional Chinese medicine is prepared from astragalus polysaccharide, lumbricus, bombyx batryticatus, ginseng, decumbent bugle herb and liquorice; the water soluble vitamin comprises vitamin B1, vitamin B2, vitamin B6, vitamin B12, 96% of envelope VC, and 35% of VC ester; the compound amino acid is composed of lysine, methionine, cystine, glutamic acid, arginine, tryptophan, phenylalanine, threonine, leucine, glycine and serine. The Chinese herbal medicine compound amino acid feed additive is mixed with normal feed for feeding animals, and can be used for speeding up the animal metabolism, whetting the appetite, prompting the growth, preventing the hypoimmunity as well as the poor growth due to deficiency of vitamin, amino acid and protein, and effectively reducing the risk in feeding.

The invention discloses a detection kit for a cystine protease inhibitor C. The kit comprises a reagent R1 and a reagent R2, wherein the R1 is a proper buffer, and the reagent R2 is formed through placing polystyrene latex particles sensitized by cystine protease inhibitor C antibodies in a proper buffer. The kit of the present invention has the advantages of high sensitivity, good specificity, good accuracy, strong anti-interference capability, and low production cost.

The invention is for the combination of EDTA, cystine, selenium, Vitamin C, Vitamin E, and zinc for anti-thrombotic effect and for the effect of restoring platelet aggregation, an integral component of thrombus formation, to normal and for the monitoring of the response to therapy with the combination. Methods for use of the components and method for performing the monitoring are included. The combination and method are particularly efficacious for vascular deficiency ailments including atherosclerotic vascular disease, reduction of ischemic cerebal event, complications from surgical procedures including restenosis, neurogenerative disease, and erectile disfunction, and vascular deficiency resulting from etiology of sepsis and chronic infection.

An organ fibrosis inhibitor, in particular, a liver fibrosis inhibitor is provided, which contains histidine, preferable together with cysteine and / or cystine as active ingredients. Owing to the combined use, a remarkable effect of inhibiting organ fibrosis, in particular, liver fibrosis can be shown. These substances are usable as the desired active ingredients in the form of a drug or in the form of a food and drink. There is also provided an organ fibrosis inhibitor comprising the active ingredients as described above either separately or as a combination of one of them with a mixture of the other two ingredients. Thus, it is possible to present organ fibrosis inhibitors such as a liver fibrosis inhibitor which are applicable in the form used in health foods for improving and maintaining liver function and foods and drinks for sick people, as well as drugs for various organ diseases caused by fibrosis such as liver diseases.

The invention provides enzyme-catalyzed disulfide bond-crosslinked natural polymer hydrogel and a preparation method thereof. The hydrogel comprises a three-dimensional net structure composed of crosslink bonds of cystamine or N,N-diacetyl-L-cystine; under the conditions that horseradish peroxidase is used as a catalyst and a phenol compound is used as an enzyme substrate, sulfydryl-grafted natural polymers are rapidly oxidized to form disulfide bonds, so that the hydrogel is obtained. According to the invention, raw materials are safe in source and environment-friendly, the product has excellent biocompatibility; reaction conditions are mild, and the operation is simple; the system is not required to be additionally added with hydrogen peroxide, and physiological activity of a loaded drug or cells is completely guaranteed.

An organ fibrosis inhibitor, in particular, a liver fibrosis inhibitor is provided, which contains histidine, preferable together with cysteine and / or cystine as active ingredients. Owing to the combined use, a remarkable effect of inhibiting organ fibrosis, in particular, liver fibrosis can be shown. These substances are usable as the desired active ingredients in the form of a drug or in the form of a food and drink. There is also provided an organ fibrosis inhibitor comprising the active ingredients as described above either separately or as a combination of one of them with a mixture of the other two ingredients. Thus, it is possible to present organ fibrosis inhibitors such as a liver fibrosis inhibitor which are applicable in the form used in health foods for improving and maintaining liver function and foods and drinks for sick people, as well as drugs for various organ diseases caused by fibrosis such as liver diseases.

A nasal passage cleaning composition according to the invention comprises water and salt as a base, and contains a mucolytic agent such as alum and / or zinc sulphate to shrink the mucosa and allow sinus passage drainage, decreasing pressure in the infected sinus an alleviates sinus headache and face ache. A preferred mucolytic agent is n-acetyl-L-cystine, which is used to dissolve or soften mucus in the nasal passages, though methyl salicylate may also be used to disintegrate crusted mucus, acting also as a topical anti-inflammatory agent and as a pain relieving agent to reduce pain and discomfort.

The present invention is directed to an improved method of treating cystinuria, utilizing the catalytic ability of cystinase to increase the rate of cystine stone dissolution.

The present invention provides cysteine and cystine prodrugs for the treatment of schizophrenia and drug addiction. The invention further encompasses pharmaceutical compositions containing prodrugs and methods of using the prodrugs and compositions for treatment of schizophrenia and drug addiction.

Cystine analogs that improve the solubility of L-cystine in urine for treatment of cystinuria and which have the structure:and pharmaceutically acceptable salts, solvates and prodrugs thereof, whereineach R and R′ pair are independently selected from (i) or (ii);(i) R and R′ are independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alcohol, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclic, and substituted or unsubstituted heteroaryl, or(ii) R and R′ together form a substituted or unsubstituted heterocyclic ring structure, or a substituted or unsubstituted heteroaryl ring structure;X is hydrogen, or an alkyl; and Y is O or S.

The invention discloses an amino acid injection, commonly known as propranolol, which relates to a pharmaceutical preparation containing 18 kinds of amino acids. The amino acid injection contains the following components per 1,000 milliliters: isoleucine, leucine, methionine, phenylalanine, threonine, tryptophan, valine, glycine, alanine, glutamic acid, aspartic acid, proline, serine, cystine, lysine hydrochloride or lysine acetate, arginine hydrochloride or arginine, histidine hydrochloride or histidine, tyrosine or acetyl tyrosine, and sodium bisulfite or sodium meta-bisulphite. The osmotic pressure ratio of the amino acid injection is lower than 1.8, which effectively reduces the pain for a patient in infusion; the added quantity of antioxidant is small, which can reduce the clinical adverse reactions; and an infusion bottle body is large, which is convenient to mix liquid in clinical application.

Objects of the present invention are to provide an oxidative stress inhibitor which is capable of suppressing the expression of a cytotoxic protein and the activation of a gene transcriptional regulatory factor taking part such expression of a cytotoxic protein and exhibits good feeling upon use and safety; to provide a method for preventing, retarding, alleviating or treating a skin change due to aging or an undesirable aesthetic skin change, both caused or promoted by an oxidative stress; and to provide a cosmetic composition or dermatologic preparation for external use comprising the oxidative stress inhibitor as an effective ingredient, and for those purposes are employed an oxidative stress inhibiting agent which comprises, as an effective ingredient, at least one selected from cysteine or cystine derivatives and the salts thereof.

Imaging agents that comprise labeled substrates of the cystine / glutamate antiporter of cells, whereby the methods of use comprise introducing the labeled agents into cells via the cystine / glutamate antiporter, which are then reduced to a labeled cysteine, and subsequently detected in the cell.

The invention discloses a hyaluronic acid / poly(N-epsilon-acryloyl-L-lysine) dual-network aquagel capable of biological reduction and a preparation method thereof. The preparation method comprises the following steps: modifying hyaluronic acid sequentially with cystamine and glycidyl methacrylate to obtain methylacryloylated hyaluronic acid, carrying out photochemical polymerization to obtain a hyaluronic acid aquagel; carrying out freeze-drying on the hyaluronic acid aquagel, impregnating in a mixed solution of a monomer N-epsilon-acryloyl-L-lysine, a crosslinking agent N,N'-bis-acryloyl-L-cystine and a water-soluble photoinitiator, and carrying out secondary photochemical polymerization to obtain the hyaluronic acid / poly(N-epsilon-acryloyl-L-lysine) dual-network aquagel. The dual-network aquagel has interpenetrating microstructure, has the characteristics of high mechanical strength, flexible and adjustable mechanical, swelling and degradation properties and the like, and is capable of biological reduction. The method has the advantages of favorable raw material economy, simple technique and short reaction time. The obtained gel has the advantages of stable structure, high strength and the like, and has favorable application prospects.

The normal temperature and sub-normal temperature in vitro heart preserving perfusate as one kind of organ preserving matter consists of basic electrolyte, energy matter and protecting matter. Each liter of the heart preserving perfusate contains NaCl 5.0-7.0 g, KCl 0.3-0.5 g, NaH2PO4 .H2O 100-150 mg, MgSO4 50-100 mg, NaHCO3 3.0-5.0 g, L-argine 70-100 mg, histidine 30-60 mg, L-cystine 50-70 mg, L-methionine 10-50 mg, levo glutamine 500-700 mg, L-lysine 100-170 mg, glycine 10-50 mg, L-isoleucine 70-150 mg, L-serine 30-50 mg, L-leucine 70-150 mg, L-tryptophane 10-20 mg, L-tyramine 80-150 mg, L-valine 70-150 mg, L-threonine 80-150 mg, choline chloride 3-8 mg, vitamin B2 0.5-3 mg, pantothenic acid 3-g mg, folic acid 3-8 mg, pyridoxal 3-10 mg, nicotinamide 3-10 mg, etc. The present invention has the effects of preserving in vitro heart efficiency, reducing rejection reaction of organ and prolonging the survival period of organ.

An external standard solution for use in the analysis of amino acid in plasma, containing,(1) at least one amino acid selected from the following components A, at a concentration of 0.0007 M to 0.49 M, and (2) (i) at least one amino acid selected from the following components B, at a concentration of 0.2 to 0.9 times of the lowest-concentration amino acid among the amino acids selected from components A, (ii) at least one amino acid selected from the following components C, at a concentration of 0.1 to 0.4 times of the lowest-concentration amino acid among amino acids selected from the components A, or (iii) at least one amino acid selected from the following components D, at a concentration of 0.05 to 0.2 times of the lowest-concentration amino acid among amino acids selected from the components A,[Components A] valine, glycine, alanine and glutamine[Components B] serine, proline, threonine, taurine, leucine, isoleucine, lysine, histidine, phenylalanine and tyrosine[Components C] asparagine, ornithine, arginine and tryptophan[Components D] glutamic acid, methionine, citrulline and cystine.

The invention relates to a crop growth regulating preparation which belongs to the technical field of crop chemical drought resistance and particularly provides an organic nutritional drought-resistance agent and a preparation method thereof. The organic nutritional drought-resistance agent is used for improving the drought resistance in crops in a planting period. In the invention, arginine, cystine, aspartic acid, vitamin B1 and vitamin B2 serve as nutritive components, and hexanoic acid 2-(diethylamino) ethyl ester, dimethyl sulfoxide, salicylic acid, choline chloride and betaine form a material combination capable of regulating physical activities of crops. The two kinds of components are used in combination, so that organic nutrients the plants lacks under a drought condition can be supplied directly, plant type can be regulated, the drought resistance in the crops can be improved, and the yield of the crops is increased. The preparation can be used for soaking seeds or sprayed or sprinkled.

A method of preventing or inhibiting L-cystine crystallization using the compounds of formula I is disclosed.R1a—O-(-A-L-)m-A-O—R1b  I,wherein A, L, R1a, R1b, and m are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of conditions that are causally related to L-cystine crystallization, such as comprising (but not limited to) kidney stones.

Methods and preparatons for treating disorders of the eye and / or causing posterior vitreous disconnection or disinsertion. Preparations containing a) urea, b) urea derivatives (e.g., hydroxyurea, thiourea), c) a non-steroidal anti-inflamatory agents, d) antmetabolites, e) urea, urea derivatives, non-enzymatic proteins, nucleosides, nucleotides and their derivatives (e.g., adenine, adenosine, cytosine, cytadine, guanine, guanitadine, guanidinium, thymidine, thimitadine, uradine, uracil, cystine), uric acid, calcium acetal salicylate, ammonium sulfate or other compound capable of causing non-enzymatic dissolution of the hyaloid membrane or e) any of the possible combinations thereof, are administered to the eye in therapeutically effective amounts.

The invention belongs to the technical field of medical animal model feed and discloses feed for preparation of an alcoholic liver animal model. The feed for mice is prepared from casein, L-cystine, DL-methionine, maltodextrin, meal cellulose, xanthan gum, choline bitartrate, a mineral premix, a vitamin premix, cholesterol, sodium cholate, fish oil, alcohol and water. The feed for preparation of an alcoholic liver animal model can gradually cause mouse alcoholic fatty liver, hepatitis and liver fibrosis. The model has features similar to human diseases and pathology has a certain development process. A modeling method is simple and easy and has a high success rate, a low death rate, good repeatability and a wide application prospect.

Disclosed is an agent for use in the treatment or prevention of inflammatory bowel disease. Also disclosed is an agent for inhibiting the production of TNF-α. A therapeutic or prophylactic agent for inflammatory bowel disease comprising at least one amino acid selected from the group consisting of lysine, histidine, phenylalanine, methionine, tryptophan, glutamine, glycine, cysteine, cystine and threonine, the amino acid being administered at a dose of 0.1 to 4000 mg / kg per day; and a TNF-α production inhibitor comprising an amino acid selected from the group consisting of histidine, phenylalanine and tryptophan, the amino acid being administered at a dose of 0.1 to 4000 mg / kg per day.

The invention relates to a high concentration glycerol-type minoxidil tincture for treating alopecia and a preparation method thereof. The high concentration glycerol-type minoxidil tincture of the invention comprises components of minoxidil, alcohol, glycerol, water-soluble azone, acids, ethylene diamine tetraacetic acid, arginine, cystine and water. Traditional propylene glycol is substituted by glycerol and water-soluble azone, so as to realize a minoxidil concentration of 5-15%, solve allergic problem caused by propylene glycol and realize a high minoxidil dissolving concentration; amino acids are added in the components to increase hair growing speed; when necessary, the arginine and / or sodium hydroxide is added with a pH buffer solution to stabilize a scalp pH at an optimum pH andavoid discomfort and hair shedding caused by pH change along with application of the hair grower. The invention employs a minoxidil step-by-step dissolving method with a short dissolving time to solve a problem of minoxidil oxidation during dissolving in a traditional technology.

Nutritional or therapeutic compositions containing glutamic acid, cystine, glycine and a selenium precursor and methods for their utilization to increase glutathione synthesis and thereby enhance the immune system are described.

The present invention provides a bacterium belonging to the family Enterobacteriaceae, which is able to produce L-cysteine and has been modified to increase the activity of the protein encoded by the dsbA gene. This bacterium is cultured in a medium, and L-cysteine, L-cystine, a derivative or precursor thereof or a mixture thereof can be collected from the medium.